» Articles » PMID: 11342585

Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells

Overview
Journal J Exp Med
Date 2001 May 9
PMID 11342585
Citations 175
Authors
Affiliations
Soon will be listed here.
Abstract

Tyrosine kinase receptors for angiogenic factors vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) are expressed not only by endothelial cells but also by subsets of hematopoietic stem cells (HSCs). To further define their role in the regulation of postnatal hematopoiesis and vasculogenesis, VEGF and Ang-1 plasma levels were elevated by injecting recombinant protein or adenoviral vectors expressing soluble VEGF(165), matrix-bound VEGF(189), or Ang-1 into mice. VEGF(165), but not VEGF(189), induced a rapid mobilization of HSCs and VEGF receptor (VEGFR)2(+) circulating endothelial precursor cells (CEPs). In contrast, Ang-1 induced delayed mobilization of CEPs and HSCs. Combined sustained elevation of Ang-1 and VEGF(165) was associated with an induction of hematopoiesis and increased marrow cellularity followed by proliferation of capillaries and expansion of sinusoidal space. Concomitant to this vascular remodeling, there was a transient depletion of hematopoietic activity in the marrow, which was compensated by an increase in mobilization and recruitment of HSCs and CEPs to the spleen resulting in splenomegaly. Neutralizing monoclonal antibody to VEGFR2 completely inhibited VEGF(165), but not Ang-1-induced mobilization and splenomegaly. These data suggest that temporal and regional activation of VEGF/VEGFR2 and Ang-1/Tie-2 signaling pathways are critical for mobilization and recruitment of HSCs and CEPs and may play a role in the physiology of postnatal angiogenesis and hematopoiesis.

Citing Articles

Placental Gene Therapy for Fetal Growth Restriction and Preeclampsia: Preclinical Studies and Prospects for Clinical Application.

Majumder S, Moriarty K, Lee Y, Crombleholme T J Clin Med. 2024; 13(18).

PMID: 39337133 PMC: 11432969. DOI: 10.3390/jcm13185647.


Dynamics of Endothelial Cell Diversity and Plasticity in Health and Disease.

Larionov A, Hammer C, Fiedler K, Filgueira L Cells. 2024; 13(15.

PMID: 39120307 PMC: 11312403. DOI: 10.3390/cells13151276.


Hematopoietic Stem Cells and Their Niche in Bone Marrow.

Kwon M, Kim B, Yoon S, Oh S, Lee D Int J Mol Sci. 2024; 25(13).

PMID: 38999948 PMC: 11241602. DOI: 10.3390/ijms25136837.


Granulocyte Colony-Stimulating Factor Improves Endothelial Progenitor Cell-Mediated Neovascularization in Mice with Chronic Kidney Disease.

Tang S, Lee Y, Tseng C, Huang P, Kuo K, Tarng D Pharmaceutics. 2023; 15(10).

PMID: 37896140 PMC: 10610103. DOI: 10.3390/pharmaceutics15102380.


Cellular and molecular mechanisms in vascular repair after traumatic brain injury: a narrative review.

Zhao Z, Yan L, Wen J, Satyanarayanan S, Yu F, Lu J Burns Trauma. 2023; 11:tkad033.

PMID: 37675267 PMC: 10478165. DOI: 10.1093/burnst/tkad033.


References
1.
Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M . Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999; 94(11):3717-21. View

2.
Huang X, Takakura N, Suda T . In vitro effects of angiopoietins and VEGF on hematopoietic and endothelial cells. Biochem Biophys Res Commun. 1999; 264(1):133-8. DOI: 10.1006/bbrc.1999.1472. View

3.
Rafii S . Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000; 105(1):17-9. PMC: 382591. DOI: 10.1172/JCI8774. View

4.
Lin Y, Weisdorf D, Solovey A, Hebbel R . Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000; 105(1):71-7. PMC: 382587. DOI: 10.1172/JCI8071. View

5.
Peichev M, Naiyer A, Pereira D, Zhu Z, Lane W, Williams M . Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000; 95(3):952-8. View